Bond Drug Patent Portfolio
Bond's Family Patents
Clinical Trials
Recent Clinical Trials by Bond:
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| Nivolumab and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma | David Bond, MD | NA |
COMPLETED
(Sep 1, 2026)
| PHASE1, PHASE2 |
| Tafasitamab and Lenalidomide Followed by Tafasitamab and ICE as Salvage Therapy for Transplant Eligible Patients With Relapsed/ Refractory Large B-Cell Lymphoma | David Bond, MD | NA |
ACTIVE NOT RECRUITING
(Jul 1, 2026)
| PHASE2 |
Explore Our Curated Drug Screens
Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List